Making A Difference PDF Print E-mail
Friday, 11 September 2009 18:31
Jessica Lewis, a Center for Student Missions team member, recently recounted a touching experience, in which she heard about and met someone with Scleroderma for the very first time. According to Jessica, "We don't always get to see the effect of what it is we are doing, but yesterday I got to see it. I am so glad I asked to deliver this meal and that I got to meet this sweet, precious lady who had such a positive outlook on life. I got to see one last time how God is working here in New York City. He knew just how to perfectly end my summer."

Read about Jessica's full experience here, on the CSM Urban Update blog. Jessica's experience reminds us, that no matter how little we can do or give, it goes some way toward making a difference in someone else's life. We hope that you do enjoy reading her story.
 
More articles :

» The Vascular Microenvironment and Systemic Sclerosis

Tracy Frech, Nathan Hatton, Boaz Markewitz, Mary Beth Scholand, Richard Cawthon, Amit Patel, and Allen SawitzkeReceived 5 April 2010; Revised 28 May 2010; Accepted 6 July 2010The role of the vascular microenvironment in the pathogenesis Systemic...

» What Are The Odds Of Having A Rare Disease?

There are over 7,000 known rare disorders or diseases, a statistic which is continually growing as medical science advances. The European Union's definition of a rare disorder or disease is a condition which affects 5 or less people in every 10,000....

» Scleroderma Study Identifies Roadblocks To Employment

In the United States, the work disability rate for people with , also known as systemic sclerosis, is two to three times that of people with some other rheumatic conditions, according to research data from investigators at The (UTHealth) Medical...

» Systemic Sclerosis Patients Treated With Oral Treprostinil Diethanolamine

Patients with effectively absorbed oral treprostinil diethanolamine, which produced a temporal association with improved cutaneous perfusion and temperature, according to study results. In a dual-center, open-label, phase 1 study, researchers...

» Placebo-controlled Study of Methotrexate in Juvenile Localised Scleroderma

According to the results of this placebo-controlled study, is an effective treatment for juvenile localised scleroderma (JLS). The authors note that JLS is a chronic progressive fibrotic process of the skin causing permanent disability and...

» Rituximab Shows Promise in Scleroderma

Rituximab (Rituxan) improved lung function in patients with , a small proof-of-principle study found.At one year, patients randomized to receive rituximab had a median 10.25% increase in forced vital capacity (FVC) compared with baseline, while...